Eli Lilly Highlights Retatrutide's Potential Beyond Upcoming Earnings

Eli Lilly is set to report its earnings on October 29, but the company emphasizes that the story of Retatrutide could be a more significant growth driver than the quarter's financial results. This suggests that Retatrutide may have a substantial impact on the company's future performance, potentially surpassing the success of Zepbound.

Originally published by gnews